Trulicity ® (dulaglutide) injection

0.75 mg/0.5 mL, 1.5 mg/0.5 mL, 3mg/0.5mL, 4.5mg/0.5mL

This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.

When starting Trulicity® (dulaglutide): can patients continue taking sulfonylureas or insulin?

Consider reducing insulin/insulin secretagogue dose when initiating Trulicity (dulaglutide).

US_cFAQ_GLP023_CONCOMITANT_SULFONYLUREA_OR_INSULIN_DOSE
US_cFAQ_GLP023_CONCOMITANT_SULFONYLUREA_OR_INSULIN_DOSE
en-US

Detailed Information

Concomitant Use With an Insulin Secretagogue or With Insulin

To reduce the risk of hypoglycemia when initiating dulaglutide treatment, consider reducing the dosage of concomitantly administered

  • insulin secretagogues, such as sulfonylureas, or
  • insulin.1

Reference

1Trulicity [package insert]. Indianapolis, IN: Eli Lilly and Company; 2021.

Date of Last Review: September 10, 2020


Contact Lilly

Call Us

If you need information about a Lilly product or want to report an Adverse Event or Product Complaint, you may call us.

Available Mon – Friday, 9am-7pm (EST), excluding holidays

Or you can

Chat with us

Chat with us

Submit a Request

Visit Us @LillyMedical